Red Sox reinstate Pivetta from injured list to face Sale, and other roster moves
The Red Sox’s Jenga-esque battle with the roster and injured list continues.
On Wednesday, the club announced they’d reinstated Nick Pivetta (mild flexor strain) and Romy Gonzalez (wrist) from the 15- and 10-day injured lists, respectively.
Pivetta will start against former rotation-mate Chris Sale in Atlanta on Wednesday night, with Gonzalez playing first and batting seventh.
To make room on the active roster, the Red Sox optioned right-hander Naoyuki Uwasawa to Triple-A Worcester and designated infielder Zack Short for assignment.
After exiting Sunday’s series finale in Minnesota with left-hamstring tightness, Rob Refsnyder will sit out again on Wednesday. Though Alex Cora noted postgame that they needed the veteran utility-man – who excels against left-handed pitching – in the lineup against Sale, the decision is precautionary. Sources told the Herald there are no plans to place Refsnyder on the injured list at the present.
More Stories
Meta and TikTok fail to halt thousands of social media addiction lawsuits
A US appeals court has rejected a challenge by Meta and TikTok, allowing wider litigation against major platforms to proceed...
Harrods returns to £84.9m profit after Al Fayed compensation payouts
Harrods returned to a pre-tax profit of £84.9 million in the year to the end of January, according to its...
Beyoncé buys out LVMH’s stake in SirDavis whisky brand
Beyoncé has acquired full control of SirDavis, the American whisky brand she established two years ago with LVMH, after the...
87% of parents want entrepreneurial skills taught in schools
More than a third of British parents (35 per cent) would rather their child start a business than go to...
Cambridge Aerospace valued at $3.4bn after raising $300m
Defence technology company Cambridge Aerospace has raised $300 million at a valuation of $3.4 billion, two years after it was...
Rare disease investment rises after US voucher renewal, UK lags
Investment in rare disease biotechs has increased since the US Food and Drug Administration’s Rare Pediatric Disease Priority Review Voucher...
